These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention. Robinson JG; Heistad DD; Fox KA Atherosclerosis; 2015 Dec; 243(2):593-7. PubMed ID: 26545013 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of subtilisin/kexin-like proprotein convertases in human atherosclerosis. Stawowy P; Kallisch H; Borges Pereira Stawowy N; Stibenz D; Veinot JP; Gräfe M; Seidah NG; Chrétien M; Fleck E; Graf K Virchows Arch; 2005 Apr; 446(4):351-9. PubMed ID: 15756593 [TBL] [Abstract][Full Text] [Related]
9. Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels. Stawowy P; Fleck E J Mol Med (Berl); 2005 Nov; 83(11):865-75. PubMed ID: 16244876 [TBL] [Abstract][Full Text] [Related]
10. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Tuñón J; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Hoefer IE; Ketelhuth DFJ; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Bäck M Cardiovasc Res; 2019 Jan; 115(1):10-19. PubMed ID: 30534957 [TBL] [Abstract][Full Text] [Related]
12. Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL. Turpeinen H; Raitoharju E; Oksanen A; Oksala N; Levula M; Lyytikäinen LP; Järvinen O; Creemers JW; Kähönen M; Laaksonen R; Pelto-Huikko M; Lehtimäki T; Pesu M Atherosclerosis; 2011 Dec; 219(2):799-806. PubMed ID: 21889147 [TBL] [Abstract][Full Text] [Related]
13. Recent advances in therapeutic targeting of inflammation in atherosclerosis. Hedin U; Matic LP J Vasc Surg; 2019 Mar; 69(3):944-951. PubMed ID: 30591299 [TBL] [Abstract][Full Text] [Related]
14. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
15. FURIN suppresses the progression of atherosclerosis by promoting macrophage autophagy. Chen H; Zhang L; Mi S; Wang H; Wang C; Jia W; Gong L; Dong H; Xu B; Jing Y; Ge P; Pei Z; Zhong L; Yang J FASEB J; 2023 May; 37(5):e22933. PubMed ID: 37093709 [TBL] [Abstract][Full Text] [Related]
16. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Stawowy P; Meyborg H; Stibenz D; Borges Pereira Stawowy N; Roser M; Thanabalasingam U; Veinot JP; Chrétien M; Seidah NG; Fleck E; Graf K Circulation; 2005 May; 111(21):2820-7. PubMed ID: 15911696 [TBL] [Abstract][Full Text] [Related]
17. Novel anti-inflammatory therapies for the treatment of atherosclerosis. Khan R; Spagnoli V; Tardif JC; L'Allier PL Atherosclerosis; 2015 Jun; 240(2):497-509. PubMed ID: 25917947 [TBL] [Abstract][Full Text] [Related]
18. Preclinical Reversal of Atherosclerosis by FDA-Approved Compound that Transforms Cholesterol into an Anti-Inflammatory "Prodrug". Mendelsohn AR; Larrick JW Rejuvenation Res; 2016 Jun; 19(3):252-5. PubMed ID: 27241174 [TBL] [Abstract][Full Text] [Related]
19. Polydatin for treating atherosclerotic diseases: A functional and mechanistic overview. Wu M; Li X; Wang S; Yang S; Zhao R; Xing Y; Liu L Biomed Pharmacother; 2020 Aug; 128():110308. PubMed ID: 32480216 [TBL] [Abstract][Full Text] [Related]
20. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease. Maranhão RC; Leite AC Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]